1. A 44-year-old man is 25 minutes into a laparoscopic Nissen fundoplication under sevoflurane anesthesia. The circulating nurse calls out that the capnograph (the monitor measuring exhaled carbon dioxide) is showing a steadily rising end-tidal CO2 despite unchanged ventilator settings and minute ventilation. Heart rate has increased from 72 to 104 bpm. Temperature is 37.8°C. The surgeon notes the abdomen feels unusually rigid. The anesthesiologist suspects malignant hyperthermia. Which of the following correctly identifies the earliest and most sensitive clinical sign of a developing MH crisis, and explains why it appears before the other signs?
A) Muscle rigidity is the earliest sign because RYR1 channel opening causes immediate, sustained myofilament cross-bridge formation before metabolic changes can develop
B) Rising end-tidal CO2 is the earliest and most sensitive sign — the massive increase in skeletal muscle metabolic rate from uncontrolled calcium-driven contracture generates CO2 faster than the lungs can eliminate it, producing this change before temperature rise or generalized rigidity become apparent
C) Hyperthermia is the earliest sign because the heat generated by uncontrolled ATP hydrolysis in muscle rapidly overwhelms the body's thermoregulatory capacity within the first few minutes of crisis onset
D) Tachycardia is the earliest sign because the sympathetic nervous system detects the rising metabolic rate via peripheral chemoreceptors and reflexively increases heart rate before muscular or respiratory signs develop
E) Metabolic acidosis detected on arterial blood gas is the earliest objective sign, preceding all clinical findings by 10–15 minutes as lactate accumulates in ischemic muscle
ANSWER: B
Rationale:
Option B is correct. Rising end-tidal CO2 (EtCO2) is the earliest and most sensitive sign of a developing malignant hyperthermia crisis. The mechanism is direct: uncontrolled calcium release from the sarcoplasmic reticulum via mutant RYR1 channels drives sustained, uncoordinated skeletal muscle contracture and massive hypermetabolism. This hypermetabolic state generates CO2 at a rate that far exceeds the body's normal CO2 production, and since the ventilator settings are fixed, the rising CO2 load is immediately reflected as an increase in end-tidal CO2 on the capnograph. This sign appears before temperature elevation because the body's thermoregulatory mechanisms (cutaneous vasodilation, sweating) can transiently buffer heat accumulation, and before generalized rigidity becomes clinically apparent because the metabolic crisis precedes the full contracture syndrome. Anesthesiologists are trained to treat an unexplained rising EtCO2 under volatile anesthesia as MH until proven otherwise.
Option A: Option A is incorrect; while muscle rigidity — particularly masseter spasm after succinylcholine — can be an early sign, generalized rigidity typically follows the metabolic signs rather than preceding them, and EtCO2 rise is consistently identified as the more sensitive early indicator.
Option C: Option C is incorrect; temperature rise is a late sign in MH — hyperthermia may develop rapidly once established (1–2°C per minute in severe crisis) but does not precede the metabolic and respiratory signs.
Option D: Option D is incorrect; tachycardia is a nonspecific sympathetic response that accompanies the crisis but is not more sensitive than the direct metabolic CO2 signal.
Option E: Option E is incorrect; arterial blood gas findings are available only after sampling and laboratory processing — they reflect the metabolic derangement but are not a real-time early warning sign in the way capnography is.
2. A 47-year-old obese woman undergoes her third halothane anesthetic in 18 months — each for minor gynecological procedures at a clinic that has not updated its agent supply. Ten days after the third procedure she develops fever, right upper quadrant pain, markedly elevated transaminases (ALT 3,400 U/L), and jaundice. Liver biopsy confirms massive hepatic necrosis consistent with immune-mediated drug-induced liver injury. Which combination of patient and exposure characteristics in this case represents the highest-risk profile for developing Type II halothane hepatotoxicity (halothane hepatitis)?
A) Male sex, low body weight, and a single prior halothane exposure more than 5 years ago
B) Pediatric age group, a single lifetime exposure, and normal hepatic enzyme levels at baseline
C) Advanced age over 70, concurrent use of acetaminophen, and a history of non-alcoholic fatty liver disease
D) Male sex, high-flow anesthesia technique, and use of a newer vaporizer with precise agent delivery
E) Female sex, obesity, middle age, and multiple prior halothane exposures at short intervals — particularly the combination of repeated exposures within months of each other, which dramatically amplifies the immune sensitization mechanism
ANSWER: E
Rationale:
Option E is correct. The risk factors for Type II halothane hepatotoxicity (halothane hepatitis) are well-characterized and reflect the immune sensitization mechanism underlying the condition. The highest-risk profile combines: female sex (women are affected approximately twice as often as men, for reasons not fully established but possibly related to differences in CYP2E1 activity or immune reactivity); obesity (increased hepatic CYP2E1 activity in obese patients generates more trifluoroacetylated protein neoantigens); middle age (peak incidence in the fourth and fifth decades); and — critically — multiple prior halothane exposures, especially at short intervals. The immune mechanism requires prior sensitization: the first exposure generates trifluoroacetylated neoantigens and primes the immune system, while subsequent exposures trigger the full cytotoxic T-lymphocyte and antibody-mediated immune attack on hepatocytes. Short intervals between exposures (months rather than years) are particularly dangerous because the sensitized immune response is still active and amplified. A family history of halothane hepatitis is an additional risk factor.
Option A: Option A is incorrect; male sex and single prior exposure are associated with lower, not higher, risk.
Option B: Option B is incorrect; children are actually at lower risk for halothane hepatitis than adults — the incidence in pediatric patients is approximately 1 in 200,000, compared to 1 in 35,000 in adults.
Option C: Option C is incorrect; while advanced liver disease increases vulnerability to any hepatotoxic insult, it is not a specific risk factor for the immune-mediated mechanism of halothane hepatitis, and acetaminophen toxicity operates through a completely different mechanism (glutathione depletion).
Option D: Option D is incorrect; male sex and technical anesthetic factors are not risk factors — the risk profile is biological and immunological, not equipment-related.
3. A 31-year-old man develops a fulminant malignant hyperthermia crisis intraoperatively. The anesthesiologist stops all triggering agents, flushes the circuit, and administers dantrolene 2.5 mg/kg IV repeated every 5 minutes. After a total of 7.5 mg/kg, the crisis resolves: end-tidal CO2 normalizes, muscle rigidity abates, temperature begins to fall, and hemodynamics stabilize. The patient is transferred to the ICU. Which of the following correctly describes the appropriate dantrolene management in the post-crisis period and the reason for it?
A) Dantrolene should be discontinued immediately once the acute crisis resolves, because continued administration causes life-threatening hepatotoxicity when given beyond the acute treatment window
B) A single additional dose of dantrolene 2.5 mg/kg IV should be given at 6 hours post-crisis and then discontinued; recurrence of MH beyond 6 hours has not been reported
C) Dantrolene infusion should be continued at 1 mg/kg IV every 4–6 hours for at least 24 hours after the acute crisis resolves, because recrudescence — re-emergence of the hypermetabolic crisis — can occur as residual triggering agent is redistributed from tissues back into the circulation
D) Post-crisis dantrolene maintenance is optional and should be guided by hourly creatine kinase (CK) measurements; dantrolene is restarted only if CK rises above 10,000 U/L
E) Dantrolene should be replaced with oral baclofen (a muscle relaxant acting on GABA-B receptors in the spinal cord) once the patient is stable enough for enteral medication, as baclofen provides equivalent RYR1 stabilization with a more favorable safety profile for prolonged use
ANSWER: C
Rationale:
Option C is correct. After successful treatment of an acute MH crisis, dantrolene must be continued as a maintenance infusion — 1 mg/kg IV every 4–6 hours for at least 24 hours — to prevent recrudescence. Recrudescence refers to re-emergence of the hypermetabolic crisis after apparent resolution, and it is a well-recognized and potentially fatal complication of MH management. The mechanism involves ongoing redistribution of residual triggering volatile agent from lipid-rich tissue depots back into the systemic circulation, which can re-trigger RYR1 channel opening in susceptible muscle even after the operating room exposure has ended. Dantrolene's continued presence maintains RYR1 channel stabilization throughout this period of redistribution risk. The patient must remain in an ICU setting with continued monitoring of temperature, EtCO2 (or arterial PCO2), electrolytes (particularly potassium — hyperkalemia from rhabdomyolysis), CK, urine output (myoglobinuria risk), and coagulation (DIC risk).
Option A: Option A is incorrect; dantrolene is not discontinued at crisis resolution — the post-crisis maintenance protocol is mandatory. Dantrolene does have hepatotoxic potential with prolonged use, but 24-hour post-crisis dosing does not constitute the prolonged exposure required to produce clinically significant liver injury, and the risk-benefit calculation strongly favors continuation.
Option B: Option B is incorrect; 6-hour post-crisis dosing is insufficient — the standard protocol specifies at least 24 hours of maintenance dosing.
Option D: Option D is incorrect; post-crisis dantrolene management is not titrated to CK levels — the protocol is time-based and based on the pharmacokinetics of volatile agent redistribution, not on biomarker thresholds.
Option E: Option E is incorrect; baclofen acts on GABA-B receptors in the spinal cord and has no effect on RYR1 channels or sarcoplasmic reticulum calcium release — it provides no protection against MH recrudescence.
4. A 29-year-old woman at 36 weeks gestation requires emergency cesarean section under general anesthesia. Her obstetric history includes a prior uterine rupture. During pre-anesthetic assessment, the anesthesiologist notes a personal and family history consistent with a hyperkalemic response to succinylcholine — a rare but potentially fatal complication in which succinylcholine triggers massive potassium efflux from muscle, causing cardiac arrest. Succinylcholine is therefore contraindicated. The anesthesiologist must still achieve rapid sequence intubation conditions. Which of the following correctly describes the appropriate alternative neuromuscular blocking strategy for this patient?
A) Rocuronium 1.2 mg/kg IV provides rapid-sequence intubation conditions comparable to succinylcholine within approximately 60 seconds; sugammadex 16 mg/kg IV must be immediately available for emergency reversal in the event of a cannot-intubate, cannot-oxygenate scenario
B) Vecuronium 0.1 mg/kg IV is the preferred alternative; its onset is identical to succinylcholine and it can be reversed with neostigmine within 2 minutes if intubation fails
C) Cisatracurium 0.2 mg/kg IV is preferred in obstetric patients because it undergoes Hofmann elimination independent of renal or hepatic function, making it the safest agent in the parturient
D) No nondepolarizing agent provides rapid-sequence conditions; when succinylcholine is contraindicated, the appropriate technique is awake fiberoptic intubation under topical anesthesia regardless of the urgency of the delivery
E) Mivacurium 0.25 mg/kg IV is the correct alternative; like succinylcholine it is metabolized by plasma cholinesterase and therefore has a similarly short duration of action without the hyperkalemia risk
ANSWER: A
Rationale:
Option A is correct. When succinylcholine is contraindicated for rapid sequence intubation (RSI), rocuronium at the high intubating dose of 1.2 mg/kg IV (three times the standard intubating dose of 0.6 mg/kg) provides neuromuscular blockade onset conditions that approach those of succinylcholine, achieving adequate intubating conditions within approximately 60 seconds. This is the accepted alternative for RSI when succinylcholine cannot be used, including in the obstetric setting. The critical requirement is that sugammadex 16 mg/kg IV — a selective relaxant binding agent that encapsulates rocuronium and reverses even profound blockade within approximately 3 minutes — must be immediately available at the time of induction. This sugammadex availability is essential because it provides a rescue pathway in a cannot-intubate, cannot-oxygenate (CICO) emergency: if the airway cannot be secured and oxygenation fails, immediate sugammadex administration rapidly restores neuromuscular function and spontaneous ventilation. The Difficult Airway Society obstetric failed intubation guidelines specifically incorporate this rocuronium/sugammadex strategy.
Option B: Option B is incorrect; vecuronium at standard doses has a significantly slower onset (3–5 minutes) than succinylcholine and is not suitable for RSI.
Option C: Option C is incorrect; while cisatracurium's Hofmann elimination is advantageous in organ failure, its onset is slow (3–5 minutes) and it is not an RSI agent.
Option D: Option D is incorrect; awake fiberoptic intubation may be appropriate for anticipated difficult airways, but rocuronium at 1.2 mg/kg is an established RSI alternative when succinylcholine is contraindicated — denying RSI conditions in an emergency cesarean is not necessary or safe.
Option E: Option E is incorrect; mivacurium is indeed metabolized by plasma cholinesterase and has a shorter duration than other nondepolarizing agents, but its onset is still slower than succinylcholine (2–3 minutes) and it does not reliably provide RSI conditions.
5. A thoracic surgeon is performing a right lower lobectomy under one-lung ventilation (OLV). The anesthesiologist is maintaining anesthesia with isoflurane at 1.2 MAC. Thirty minutes into OLV, SpO2 has fallen to 91% despite FiO2 of 1.0. The surgeon has not yet requested any change in technique. Which of the following interventions most directly addresses the pharmacological contribution to the hypoxemia, and what is the mechanism?
A) Switch to desflurane, which has a lower blood-gas solubility coefficient and therefore redistributes away from pulmonary vasculature more rapidly, restoring HPV within minutes
B) Increase the tidal volume on the ventilated lung to recruit collapsed alveoli and increase mean airway pressure, which will passively redirect blood flow away from the non-ventilated lung
C) Add nitrous oxide 50% to the inspired gas mixture, which augments HPV in the ventilated lung by raising alveolar oxygen tension and thereby improving overall ventilation-perfusion matching
D) Reduce the isoflurane concentration to ≤0.5 MAC (supplementing with IV agents to maintain adequate anesthetic depth), because volatile agents inhibit hypoxic pulmonary vasoconstriction in a dose-dependent manner — at 1.2 MAC, HPV suppression is substantial, increasing shunt through the collapsed lung; reducing to ≤0.5 MAC partially restores HPV and reduces shunt fraction
E) Increase the isoflurane concentration to 1.5 MAC to deepen the anesthetic, which will reduce sympathetic tone to the pulmonary vasculature and allow passive HPV recovery through vasomotor normalization
ANSWER: D
Rationale:
Option D is correct. Volatile halogenated anesthetic agents inhibit hypoxic pulmonary vasoconstriction (HPV) in a dose-dependent manner. HPV is the reflex vasoconstriction of pulmonary arterioles supplying hypoxic (poorly ventilated) lung segments — during OLV, it normally reduces blood flow through the collapsed non-ventilated lung by 40–50%, limiting the intrapulmonary shunt that causes hypoxemia. At 1 MAC, volatile agent-induced HPV inhibition is substantial; at 1.2 MAC it is even more pronounced. The shunt fraction through the collapsed lung is correspondingly increased, worsening arterial oxygenation. The pharmacological intervention is to reduce the volatile agent to ≤0.5 MAC — a concentration at which HPV inhibition is much less — and supplement with propofol infusion, opioids, or other IV agents to maintain adequate anesthetic depth. This partial restoration of HPV reduces shunt flow through the operative lung and is a standard first-line intervention for refractory hypoxemia during OLV under volatile anesthesia.
Option A: Option A is incorrect; switching between volatile agents does not restore HPV — all halogenated volatile agents inhibit HPV, and the relevant variable is concentration (MAC), not the specific agent or its solubility coefficient.
Option B: Option B is incorrect; increasing tidal volume may recruit atelectatic alveoli in the ventilated lung but does not directly address HPV inhibition in the non-ventilated lung, and high tidal volumes carry their own risks (barotrauma, volutrauma) during OLV.
Option C: Option C is incorrect; nitrous oxide does not augment HPV — it has minimal HPV effects and does not improve HPV in the ventilated lung; furthermore, adding N₂O reduces FiO₂, which is counterproductive when hypoxemia is the problem.
Option E: Option E is incorrect; increasing volatile agent concentration further increases HPV inhibition — the exact opposite of what is required.
6. A 58-year-old man with pulmonary tuberculosis being treated with isoniazid (a first-line antituberculosis drug) requires elective inguinal hernia repair under general anesthesia. The anesthesiologist reviewing his medications notes that isoniazid is a known inducer of CYP2E1 — the hepatic enzyme primarily responsible for the oxidative metabolism of volatile halogenated anesthetics to inorganic fluoride. She is selecting a volatile maintenance agent. Which of the following best describes why isoniazid co-administration is a specific concern when considering enflurane as the maintenance agent in this patient?
A) Isoniazid competitively inhibits CYP2E1, reducing enflurane metabolism and causing accumulation of the parent compound to anesthetic overdose concentrations
B) Isoniazid induces CYP2E1, increasing enflurane metabolism and generating higher serum inorganic fluoride concentrations than would otherwise occur; enflurane already generates fluoride levels of 20–30 μmol/L under standard conditions — approaching but generally not exceeding the ~50 μmol/L nephrotoxic threshold — and CYP2E1 induction by isoniazid can push fluoride levels above this threshold, increasing the risk of renal tubular toxicity
C) The concern is not renal but hepatic: isoniazid's CYP2E1 induction dramatically increases enflurane's trifluoroacetylation fraction from 2–5% to above 20%, placing the patient's hepatitis risk at the same level as halothane
D) Isoniazid reduces renal blood flow by inhibiting prostaglandin synthesis in the kidney; combined with enflurane's hemodynamic effects, this produces additive nephrotoxicity independent of fluoride generation
E) The interaction is pharmacodynamic rather than pharmacokinetic: isoniazid and enflurane both lower the seizure threshold, and co-administration substantially increases the risk of intraoperative tonic-clonic seizures that are refractory to standard anticonvulsant treatment
ANSWER: B
Rationale:
Option B is correct. Enflurane undergoes approximately 2–5% hepatic metabolism via CYP2E1, generating serum inorganic fluoride concentrations in the range of 20–30 μmol/L under standard conditions. This approaches but generally does not exceed the ~50 μmol/L threshold associated with fluoride-induced renal tubular toxicity (the nephrogenic diabetes insipidus syndrome characterized by vasopressin-resistant inability to concentrate urine, first described with methoxyflurane). Isoniazid is a well-characterized CYP2E1 inducer — it upregulates CYP2E1 expression, increasing the enzyme's capacity to metabolize enflurane to fluoride. In patients taking isoniazid, enflurane metabolism is accelerated, and serum fluoride concentrations can approach or exceed the 50 μmol/L nephrotoxic threshold. This interaction has clinical significance particularly in patients with pre-existing renal impairment, where even subclinical fluoride-induced tubular dysfunction may be consequential. The practical implication is that enflurane should be avoided or used with caution in patients receiving isoniazid, and agents with very low fluoride-generating potential (desflurane, isoflurane, or propofol TIVA) are preferable.
Option A: Option A is incorrect; isoniazid induces (upregulates), not inhibits, CYP2E1 — the effect is increased, not decreased, enflurane metabolism.
Option C: Option C is incorrect; CYP2E1 induction increases fluoride generation but does not convert enflurane's metabolic pathway to a trifluoroacetylating one; the degree of trifluoroacetylation is a property of the molecular structure of the volatile agent and its CYP2E1 metabolic fate, not simply proportional to the total fraction metabolized. Even with CYP2E1 induction, enflurane's trifluoroacetylation fraction would not approach halothane's 20%.
Option D: Option D is incorrect; isoniazid does not inhibit prostaglandin synthesis — that mechanism describes NSAIDs.
Option E: Option E is incorrect; while enflurane (particularly at high concentrations or with hypocapnia) has pro-convulsant properties that are a recognized clinical concern, this pharmacodynamic interaction with isoniazid is not the primary reason isoniazid co-administration is flagged in the context of volatile agent selection.
7. A 38-year-old man is scheduled for elective laparoscopic cholecystectomy. His brother recently survived a confirmed MH crisis under desflurane. During pre-anesthetic assessment, the patient states he received halothane anesthesia uneventfully at age 12 for a tonsillectomy and again at age 22 for a broken arm. He asks whether this means he is definitely not MH-susceptible. Which of the following is the correct response, and why?
A) Two prior uneventful volatile anesthetic exposures confirm that he is MH-safe; MH is a penetrant genetic disorder that would have manifested by the second exposure in a truly susceptible individual
B) His prior uneventful exposures reduce his probability of MH susceptibility to below 5%; he can receive a volatile anesthetic for this procedure with standard monitoring
C) His prior uneventful exposures are reassuring only if both procedures lasted longer than 2 hours; brief volatile anesthetic exposures are insufficient to trigger MH in susceptible individuals and therefore provide no information about susceptibility status
D) His prior uneventful halothane exposures are irrelevant because halothane has been reformulated and the current agent does not trigger MH; only newer agents (sevoflurane, desflurane) are true MH triggers
E) Prior uneventful volatile anesthetic exposure does not exclude MH susceptibility — MH has variable penetrance and the triggering of a crisis depends on multiple factors including the specific agent, duration, and individual threshold; a susceptible individual may tolerate one or more exposures before a crisis occurs; with a confirmed first-degree relative, this patient should receive a non-triggering anesthetic and be referred for CHCT or genetic counseling
ANSWER: E
Rationale:
Option E is correct. This is one of the most clinically important points in MH management and a common source of dangerous false reassurance. Prior uneventful volatile anesthetic exposure does not exclude MH susceptibility. MH susceptibility is an autosomal dominant pharmacogenetic trait, but its clinical expression (triggering of an acute crisis) is not invariant — it depends on multiple variables including the specific triggering agent used, the dose and duration of exposure, the patient's individual RYR1 variant and its functional severity, and other factors not fully characterized. A genetically susceptible individual may receive one, two, or even more volatile anesthetics without crisis, and then develop a fulminant MH event on a subsequent exposure. This variable penetrance means that a negative anesthetic history provides no diagnostic safety guarantee. In this patient, a confirmed first-degree relative (brother) with MH crisis creates a 50% prior probability of susceptibility — sufficient to mandate a non-triggering anesthetic technique (TIVA with propofol, opioids, and nondepolarizing agents) for any elective procedure, and referral for CHCT or genetic counseling.
Option A: Option A is incorrect; MH does not have the property of invariably manifesting by the second exposure — variable penetrance is a defining characteristic of the condition.
Option B: Option B is incorrect; prior exposures do not meaningfully reduce the calculated risk in a patient with a confirmed first-degree relative — the 50% prior probability from familial genetics is not substantially modified by negative anesthetic history given the variable penetrance of MH.
Option C: Option C is incorrect; there is no established minimum duration of volatile anesthetic exposure required to trigger MH — crises can develop rapidly (within minutes) or more gradually; brief exposures do not provide a reliable safety test.
Option D: Option D is incorrect; halothane has not been reformulated — it is the same molecule it has always been, and all original halogenated volatile agents including halothane, isoflurane, sevoflurane, and desflurane remain MH triggers.
8. A 35-year-old woman undergoes routine cholecystectomy under halothane anesthesia. Routine liver function tests drawn 3 days postoperatively show mild transaminase elevation (ALT 78 U/L, AST 64 U/L — roughly twice the upper limit of normal). She is asymptomatic, afebrile, and clinically well. Which of the following best characterizes this finding, and distinguishes it from the more serious form of halothane hepatotoxicity?
A) This pattern represents early Type II halothane hepatitis and requires immediate liver biopsy, immunosuppressive therapy, and listing for liver transplant evaluation
B) Mild transaminase elevation after halothane anesthesia always reflects pre-existing occult liver disease unmasked by the surgical stress; halothane itself does not cause any degree of hepatic enzyme elevation at routine doses
C) This pattern is consistent with Type I halothane hepatotoxicity — a mild, self-limiting transaminase elevation observed in up to 20–30% of patients after halothane exposure, caused by anesthesia-related hepatic oxygen supply-demand imbalance and direct halothane-induced lipid peroxidation; it resolves spontaneously and carries no serious clinical sequelae, in contrast to Type II halothane hepatitis, which is rare (approximately 1 in 35,000 exposures in adults), immune-mediated, frequently fatal, and associated with fever, jaundice, and massive hepatic necrosis
D) This transaminase elevation indicates subclinical compound A nephrotoxicity; halothane generates compound A under low-flow conditions, which cross-reacts with hepatic CYP enzymes and produces hepatocyte injury
E) Mild transaminase elevation after halothane is caused by isoflurane contamination of the halothane preparation; pure halothane produces no hepatic enzyme changes under any circumstances
ANSWER: C
Rationale:
Option C is correct. Halothane produces two clinically distinct forms of hepatic dysfunction with completely different mechanisms, incidences, and clinical significance. Type I halothane hepatotoxicity is a mild, subclinical transaminase elevation (typically 2–3 times the upper limit of normal) observed in up to 20–30% of patients following halothane anesthesia. It is caused by a combination of anesthesia-induced reduction in hepatic oxygen delivery (hepatic blood flow reduction → zone 3 centrilobular hypoxic injury) and direct hepatocyte lipid peroxidation by halothane. It is self-limiting, resolves without intervention, and requires no specific treatment. Type II halothane hepatotoxicity — halothane hepatitis — is an entirely different entity: it is rare (approximately 1 in 35,000 adult exposures), immune-mediated (via trifluoroacetylated neoantigen generation and cytotoxic T-lymphocyte attack), clinically severe (fever 3–7 days post-exposure, marked jaundice, transaminases in the thousands), and frequently fatal (mortality approximately 10–50% in fulminant cases) without liver transplantation. The ability to distinguish these two entities prevents both under-reaction (treating Type I as benign when it is) and over-reaction (treating mild post-anesthetic transaminase elevation as fulminant immune hepatitis).
Option A: Option A is incorrect; mild, asymptomatic transaminase elevation without fever or jaundice is consistent with Type I, not Type II — immediate transplant evaluation is not indicated.
Option B: Option B is incorrect; Type I halothane hepatotoxicity is a real and well-characterized direct pharmacological effect of halothane, not a manifestation of pre-existing liver disease.
Option D: Option D is incorrect; compound A is specific to sevoflurane, not halothane, and its toxic effects are renal rather than hepatic.
Option E: Option E is incorrect; pure halothane does produce hepatic enzyme changes (Type I) in a significant fraction of patients — this is a direct pharmacological effect, not a contaminant issue.
9. An anesthesiologist performs rapid sequence induction for emergency cesarean section in a 34-year-old woman at 39 weeks gestation. After propofol and succinylcholine, laryngoscopy reveals a Cormack-Lehane grade 4 view (no laryngeal structures visible). Two intubation attempts fail. SpO2 is 94% and falling. The surgeon states the fetal heart rate tracing shows late decelerations. Which of the following most accurately describes the correct sequence of actions according to established failed intubation management principles in obstetrics?
A) Declare failed intubation, call for help, focus on maintaining maternal oxygenation as the primary objective — insert a supraglottic airway device (such as a laryngeal mask airway) to secure ventilation, then make the decision whether to wake the patient or proceed with surgery through the supraglottic airway based on the urgency of the maternal-fetal situation; do not persist with repeated laryngoscopy attempts, which increase airway trauma and the risk of cannot-oxygenate progression
B) Immediately perform a surgical airway (cricothyrotomy) after the second failed laryngoscopy attempt, because supraglottic airway devices are contraindicated in pregnant patients due to full-stomach aspiration risk
C) Administer a second dose of succinylcholine and attempt a third laryngoscopy with a different blade, because the muscle relaxation from the first dose may have been incomplete; three total attempts are the standard before declaring failed intubation
D) Abandon general anesthesia entirely and convert to spinal anesthesia while the patient is still apneic from succinylcholine, because neuraxial techniques carry lower aspiration risk than continued attempts at tracheal intubation
E) Perform awake cricothyroid membrane puncture with a transtracheal jet ventilation catheter, which provides definitive oxygenation without requiring laryngoscopy and is the first-line rescue technique in the obstetric failed intubation algorithm
ANSWER: A
Rationale:
Option A is correct. The management of failed intubation in the obstetric patient follows a structured algorithm established by the Difficult Airway Society (DAS) obstetric guidelines. The core principle is that oxygenation is the primary objective — not tracheal intubation. After a failed intubation declaration, the immediate priority is to maintain maternal oxygenation by inserting a supraglottic airway device (the laryngeal mask airway, or LMA, is the first-line rescue device). The clinical decision that follows is whether to wake the patient — appropriate when surgery is not immediately life-saving and the airway can be secured electively — or to proceed with surgery through the supraglottic airway, appropriate when immediate delivery is required to save fetal or maternal life and oxygenation through the LMA is adequate. Repeated laryngoscopy attempts beyond two are strongly discouraged because each attempt increases airway trauma, edema, and bleeding, converting a difficult intubation into a cannot-oxygenate emergency.
Option B: Option B is incorrect; surgical airway (cricothyrotomy) is reserved for the cannot-intubate, cannot-oxygenate (CICO) scenario — when all oxygenation methods including supraglottic airway have failed. LMA is not contraindicated in obstetric patients for rescue oxygenation; it is the specified first-line rescue device in the DAS obstetric algorithm.
Option C: Option C is incorrect; administering a second succinylcholine dose and attempting a third laryngoscopy is explicitly contrary to failed intubation guidelines — persisting with repeated attempts is the principal cause of progression to cannot-oxygenate emergencies.
Option D: Option D is incorrect; spinal anesthesia in an apneic patient who has received general anesthetic induction is not a standard or safe technique — positioning, cooperation, and time requirements make this impractical and dangerous in this scenario.
Option E: Option E is incorrect; transtracheal jet ventilation is a rescue technique for CICO that is not part of the primary failed intubation algorithm and carries significant risks (surgical expertise required, barotrauma risk); the supraglottic airway is the correct first-line rescue device.
10. A hospital's anesthesia quality committee is reviewing its low-flow sevoflurane protocol. One committee member argues that all sevoflurane cases should maintain fresh gas flows of at least 2 L/min to prevent compound A nephrotoxicity. Another argues this is unnecessary because compound A has never been shown to cause clinically significant renal injury in humans. A third notes that some regulatory jurisdictions mandate the 2 L/min recommendation while others do not. Which of the following most accurately characterizes the current scientific and regulatory status of compound A nephrotoxicity?
A) Compound A nephrotoxicity in humans is well-established; multiple randomized controlled trials have demonstrated a statistically significant increase in serum creatinine and urinary biomarkers of tubular injury in patients receiving low-flow sevoflurane compared to high-flow sevoflurane or desflurane
B) The 2 L/min recommendation has been abandoned by all major regulatory agencies following a 2020 meta-analysis demonstrating equivalent renal outcomes at fresh gas flows as low as 0.5 L/min; the debate is now considered closed
C) Compound A nephrotoxicity in humans is a theoretical risk only in patients with pre-existing CKD stage 4 or 5; patients with normal renal function are fully protected because healthy nephrons can detoxify compound A before it accumulates to toxic concentrations
D) Compound A nephrotoxicity is well-characterized in rats but has not been demonstrated to cause clinically significant renal injury in humans across multiple well-designed clinical trials, including in patients with pre-existing renal impairment; the 2 L/min fresh gas flow recommendation that exists in some jurisdictions is a precautionary regulatory measure rather than a response to demonstrated human nephrotoxicity — the scientific consensus is that the rat beta-lyase pathway responsible for compound A activation is far less active in humans
E) Compound A nephrotoxicity risk is equivalent to that of methoxyflurane; both agents produce the same intrarenal fluoride concentrations, and the 2 L/min recommendation is designed to keep sevoflurane exposure below the same threshold that caused methoxyflurane nephrotoxicity
ANSWER: D
Rationale:
Option D is correct. This question asks the clinician to navigate a genuine area of regulatory-scientific complexity and identify the most accurate characterization of the evidence. The scientific consensus, supported by multiple prospective clinical trials including studies specifically enrolling patients with pre-existing renal impairment, is that compound A does not produce clinically significant nephrotoxicity in humans at concentrations encountered during low-flow sevoflurane anesthesia. The mechanistic explanation — that the rat cysteine conjugate beta-lyase pathway responsible for activating compound A to nephrotoxic sulfur conjugates is far less active in human kidneys — accounts for the species difference. The 2 L/min fresh gas flow recommendation exists in some regulatory jurisdictions (including the FDA label in the United States) as a precautionary measure, not because human nephrotoxicity has been demonstrated. Other jurisdictions and anesthesia societies have concluded the evidence does not support a mandatory flow restriction. The quality committee member arguing for the precautionary recommendation and the member arguing against it based on human clinical trial data are both accurately representing parts of the picture; the most complete characterization is Option D.
Option A: Option A is incorrect; no clinical trials have demonstrated a significant increase in clinically meaningful nephrotoxicity with low-flow sevoflurane — the statement inverts the actual evidence.
Option B: Option B is incorrect; the 2 L/min recommendation has not been universally abandoned, and regulatory positions vary by jurisdiction — this overstates the resolution of the debate.
Option C: Option C is incorrect; the species difference in beta-lyase activity applies to all humans regardless of renal function — it is not limited to patients with normal kidneys.
Option E: Option E is incorrect; the mechanism differs fundamentally between methoxyflurane (intrarenal metabolism generating high local fluoride) and sevoflurane/compound A (vinyl halide via circuit degradation, not fluoride toxicity) — these are not equivalent nephrotoxic mechanisms.
11. A 52-year-old man with a history of hypertension managed with verapamil (a calcium channel blocker — a drug that blocks voltage-gated L-type calcium channels in cardiac and vascular smooth muscle) develops MH crisis intraoperatively. The anesthesia team initiates the MH protocol: volatile agent discontinued, circuit flushed, dantrolene 2.5 mg/kg IV administered. Heart rate is 128 bpm and an arrhythmia develops on the monitor. A junior resident suggests administering IV verapamil for rate control, given the patient's history of responding well to it. Which of the following correctly identifies the appropriate response to this suggestion?
A) Verapamil is appropriate in this setting because MH-associated tachyarrhythmias are driven by catecholamine excess, and calcium channel blockade at the cardiac level will reduce heart rate without interacting with dantrolene's mechanism at the sarcoplasmic reticulum
B) Calcium channel blockers — including verapamil — are contraindicated during dantrolene treatment for MH because the combination produces serious adverse interactions: hyperkalemia, myocardial depression, and cardiovascular collapse have been reported when calcium channel blockers are administered concurrently with dantrolene; amiodarone is the preferred antiarrhythmic agent in this context
C) Verapamil is contraindicated specifically because it blocks L-type calcium channels on the sarcoplasmic reticulum, directly competing with dantrolene's RYR1-stabilizing effect and worsening the calcium dysregulation underlying MH
D) The concern with verapamil in MH is pharmacokinetic: dantrolene inhibits CYP3A4, the primary enzyme responsible for verapamil metabolism, causing verapamil plasma concentrations to rise to toxic levels
E) Calcium channel blockers are relatively contraindicated only if the patient is also receiving succinylcholine; once the triggering agents are stopped and dantrolene has been given, the contraindication is lifted and verapamil can be safely titrated for rate control
ANSWER: B
Rationale:
Option B is correct. Calcium channel blockers are contraindicated in patients receiving dantrolene for MH treatment — this is an established and important drug interaction with potentially fatal consequences. The adverse interaction between dantrolene and calcium channel blockers (particularly verapamil but also diltiazem and dihydropyridines to varying degrees) produces a combination of effects: hyperkalemia (dantrolene in the context of MH is associated with rhabdomyolysis and potassium release from injured muscle, and calcium channel blockers can exacerbate potassium-related cardiac toxicity), myocardial depression (both dantrolene and calcium channel blockers have negative inotropic properties, and their combination can produce cardiovascular collapse), and potentially fatal arrhythmias. Animal studies and case reports have documented this interaction, and it is specifically listed as a contraindication in dantrolene prescribing information. The appropriate antiarrhythmic for MH-associated arrhythmias is amiodarone; the arrhythmia typically resolves with correction of the metabolic derangements (acidosis, hyperkalemia, hyperthermia) rather than requiring specific antiarrhythmic therapy.
Option A: Option A is incorrect; verapamil is not appropriate — the dantrolene-calcium channel blocker interaction is contraindicated regardless of the arrhythmia mechanism.
Option C: Option C is incorrect; verapamil blocks plasma membrane L-type calcium channels, not sarcoplasmic reticulum calcium release channels (RYR1) — these are pharmacologically distinct. The contraindication is a pharmacodynamic interaction producing cardiac toxicity, not a direct competition at the RYR1 site.
Option D: Option D is incorrect; the contraindication is pharmacodynamic (cardiac depression, hyperkalemia), not pharmacokinetic — dantrolene does not meaningfully inhibit CYP3A4.
Option E: Option E is incorrect; the calcium channel blocker contraindication during dantrolene treatment applies throughout the treatment period, not only in the presence of succinylcholine.
12. During a vaginal delivery, the obstetrician encounters an acute uterine inversion — the fundus of the uterus has turned inside out through the cervix, a life-threatening emergency requiring immediate manual uterine reduction. She asks the anesthesiologist for rapid pharmacological uterine relaxation to allow reduction without traumatizing the uterine tissue. The patient is conscious and has a functioning epidural for labor analgesia. General anesthesia with a high-dose volatile agent is being considered as one approach. Which of the following pharmacological alternatives provides rapid uterine relaxation without requiring induction of general anesthesia, and what is its mechanism?
A) Oxytocin 10 units IV bolus provides uterine relaxation by transiently overwhelming the myometrial oxytocin receptor and producing receptor desensitization, allowing a brief window of reduced contractility during which manual reduction can be performed
B) Misoprostol 800 mcg sublingual produces uterine relaxation within 2 minutes via prostaglandin E1 receptor agonism on myometrial smooth muscle; it is the preferred agent because it does not cause systemic hypotension
C) Magnesium sulfate 4 g IV over 10 minutes produces immediate uterine relaxation by competing with calcium at voltage-gated channels in myometrial smooth muscle cells, with onset within 60 seconds of administration
D) Terbutaline 250 mcg IV is the preferred agent; as a beta-2 adrenoceptor agonist it relaxes uterine smooth muscle rapidly and does not affect systemic vascular resistance, making it hemodynamically neutral in this setting
E) Nitroglycerin 100–200 mcg IV produces rapid, titratable uterine relaxation through nitric oxide-mediated smooth muscle relaxation; it acts within 60–90 seconds, avoids the need for general anesthesia, and can be delivered in small IV bolus doses — its brief duration of action and transient hypotension are manageable with positional adjustment and IV fluid bolus
ANSWER: E
Rationale:
Option E is correct. Nitroglycerin — a nitric oxide donor that produces smooth muscle relaxation via cGMP-mediated reduction in intracellular calcium — is the pharmacological agent of choice for emergent uterine relaxation in situations where general anesthesia is not required or is undesirable. At doses of 100–200 mcg IV (or 400–800 mcg sublingually via metered dose inhaler), nitroglycerin produces rapid uterine relaxation (onset 60–90 seconds) of brief duration (1–2 minutes), making it well-suited to a time-limited obstetric procedure. It has been used successfully for uterine inversion, retained placenta requiring manual removal, and external cephalic version. The principal side effect is transient hypotension from systemic vasodilation (nitric oxide relaxes all smooth muscle), which is generally managed with head-down positioning, IV fluid bolus, and where necessary a small dose of ephedrine or phenylephrine. The brief duration of action is an advantage in this setting — uterine relaxation is needed only long enough to complete the manual reduction, after which uterotonic agents are given.
Option A: Option A is incorrect; oxytocin contracts rather than relaxes the uterus — it is the primary uterotonic agent and would worsen, not improve, a uterine inversion that requires relaxation for manual reduction.
Option B: Option B is incorrect; misoprostol is a uterotonic prostaglandin (used to treat postpartum hemorrhage by stimulating uterine contraction) — it contracts, not relaxes, the uterus.
Option C: Option C is incorrect; while magnesium sulfate has some uterine relaxant properties at high doses, its onset at 4 g over 10 minutes is too slow for the acute inversion emergency, and it is not the standard pharmacological agent for this indication.
Option D: Option D is incorrect; terbutaline does cause uterine relaxation via beta-2 agonism and has been used as a tocolytic, but it is not the preferred agent for acute obstetric emergencies requiring immediate uterine relaxation — it also produces significant tachycardia, which is problematic in a hemodynamically stressed obstetric patient, and its onset and duration are less predictable than nitroglycerin in this acute setting.
13. An anesthesiologist is managing a 2-hour abdominal procedure under sevoflurane anesthesia. She uses a weight-based dose of rocuronium for intubation — the same dose she routinely uses with propofol-based TIVA. Forty-five minutes into the case, train-of-four (TOF) monitoring shows zero twitches, indicating complete neuromuscular blockade. She had not anticipated this depth of block at this point in the case. Which of the following best explains the finding and identifies the most important monitoring implication?
A) The unexpected depth of block is caused by sevoflurane-induced hypothermia, which slows rocuronium redistribution from the neuromuscular junction to plasma — TOF monitoring is unnecessary because hypothermia reverses with warming
B) Sevoflurane has reduced the plasma protein binding of rocuronium, increasing its free fraction and pharmacological effect — the solution is to reduce the rocuronium dose on the next bolus by 50% without changing the monitoring protocol
C) Volatile halogenated anesthetics potentiate nondepolarizing neuromuscular blockade — at 1 MAC, most volatile agents reduce the required dose of a nondepolarizing agent by approximately 20–30% compared to IV-based anesthesia; the same weight-based rocuronium dose therefore produces deeper and more prolonged blockade under sevoflurane than under propofol, and TOF monitoring is essential throughout volatile agent anesthesia to guide dosing and time reversal appropriately
D) The zero-twitch TOF result indicates phase II block — rocuronium has desensitized the nicotinic receptor in a manner similar to succinylcholine with repeated dosing, and the appropriate management is to avoid neostigmine reversal and allow spontaneous recovery only
E) Zero TOF twitches at 45 minutes confirms hepatic rocuronium accumulation due to sevoflurane-induced reduction in hepatic blood flow; the primary intervention is to increase fresh gas flow to 6 L/min to restore hepatic perfusion and accelerate rocuronium clearance
ANSWER: C
Rationale:
Option C is correct. Volatile halogenated anesthetic agents potentiate nondepolarizing neuromuscular blockade through multiple mechanisms: direct inhibition of nicotinic acetylcholine receptor channel opening (reducing the probability of channel activation even when acetylcholine is present), presynaptic reduction of acetylcholine release from the motor nerve terminal, and enhanced postjunctional sensitivity to competitive blocking agents. At 1 MAC, this potentiation reduces the required dose of a nondepolarizing agent by approximately 20–30% compared to propofol-based total intravenous anesthesia. When an anesthesiologist uses the same weight-based dose of rocuronium under volatile anesthesia as under propofol, the result is a deeper and more prolonged block than anticipated. This has two critical clinical implications: (1) TOF monitoring is mandatory during volatile agent anesthesia — it is the only reliable method to detect unexpected block depth and guide both additional dosing and timing of reversal; (2) at the time of reversal, residual volatile agent continues to potentiate the block and may impair neostigmine-mediated reversal until adequate agent washout is achieved.
Option A: Option A is incorrect; sevoflurane at clinical concentrations does not produce clinically significant hypothermia, and the mechanism of block potentiation is pharmacodynamic (NMJ effects), not pharmacokinetic (redistribution slowing).
Option B: Option B is incorrect; volatile agents do not reduce rocuronium plasma protein binding — this is not the mechanism of NMJ potentiation.
Option D: Option D is incorrect; phase II block is a phenomenon associated with repeated or prolonged succinylcholine administration, not with nondepolarizing agents — rocuronium cannot produce phase II block.
Option E: Option E is incorrect; while sevoflurane does reduce hepatic blood flow, the relevant mechanism for the unexpected block depth is NMJ potentiation, not altered rocuronium clearance; and increasing fresh gas flow does not restore hepatic perfusion.
14. During pre-anesthetic preparation for emergency cesarean section under general anesthesia, the anesthesiologist insists on pre-oxygenating the patient with 100% oxygen for 3 minutes of tidal volume breathing before induction, despite the surgeon's pressure to proceed immediately. A medical student asks why pre-oxygenation is so critically important in the parturient specifically — more so than in a non-pregnant adult of similar age and body habitus. Which of the following most accurately explains the physiological basis for the parturient's heightened vulnerability to hypoxemia during apnea?
A) Pregnancy simultaneously reduces functional residual capacity (FRC) — the volume of gas remaining in the lungs after a normal exhalation, which serves as the oxygen reservoir during apnea — due to diaphragmatic elevation by the gravid uterus, while also increasing basal oxygen consumption due to the metabolic demands of the fetus, placenta, and augmented maternal cardiac work; together these changes mean that the parturient's oxygen stores deplete faster and her apnea time to critical desaturation is markedly shorter than in a non-pregnant adult
B) The parturient is more vulnerable because progesterone increases the rate of alveolar collapse during apnea by reducing surfactant production, making atelectasis develop more rapidly during the apnea period after induction
C) The primary vulnerability is reduced hemoglobin concentration from dilutional anemia of pregnancy; with lower hemoglobin, oxygen-carrying capacity is reduced, and arterial desaturation occurs more rapidly when apneic breathing stops delivering oxygen to the alveoli
D) The parturient develops hypoxemia during apnea faster than non-pregnant patients because the fetal circulation continuously extracts oxygen from the maternal venous return, creating a competing oxygen sink that accelerates depletion of the maternal arterial oxygen reserve
E) Pre-oxygenation is critically important in the parturient because the increased tidal volume of pregnancy causes preferential distribution of the pre-oxygenation gas to the upper lobes, leaving the lower lobes with a nitrogen-oxygen mixture that denitrogenates slowly; the 3-minute protocol ensures complete lower lobe denitrogenation
ANSWER: A
Rationale:
Option A is correct. The parturient is uniquely vulnerable to rapid oxygen desaturation during apnea due to two simultaneous and synergistic physiological changes of pregnancy. First, functional residual capacity (FRC) — the lung volume remaining after a normal exhalation, which represents the body's oxygen reservoir available during apnea — is reduced by approximately 20% in the term parturient, primarily due to diaphragmatic elevation by the gravid uterus reducing the volume of the thoracic cavity available for lung expansion. Second, basal oxygen consumption is increased by approximately 20% at term, driven by the metabolic demands of the fetoplacental unit, the increased maternal cardiac work of pregnancy, and the augmented ventilatory muscle effort. The combination of a smaller oxygen reservoir (reduced FRC) and faster depletion of that reservoir (increased O₂ consumption) means the parturient desaturates from full pre-oxygenation to critical levels (SpO₂ <90%) in approximately 3–4 minutes of apnea, compared to 8–10 minutes in a non-pregnant adult. This compressed apnea window makes complete pre-oxygenation not merely standard practice but a genuine safety-critical intervention, since failed intubation management takes time.
Option B: Option B is incorrect; progesterone does not reduce surfactant production — surfactant synthesis is actually increased in pregnancy to support fetal lung development. Atelectasis formation during apnea is a real phenomenon but is not the primary mechanism of the parturient's accelerated desaturation.
Option C: Option C is incorrect; while dilutional anemia of pregnancy does reduce hemoglobin, the primary mechanism of rapid desaturation is the FRC/O₂ consumption imbalance — the hemoglobin effect is secondary.
Option D: Option D is incorrect; fetal oxygen extraction from maternal circulation is a continuous process that does not specifically accelerate during maternal apnea — the fetus extracts oxygen from the uteroplacental circulation at a relatively constant rate regardless of maternal ventilation status over the short term.
Option E: Option E is incorrect; the distribution of pre-oxygenation gas is not meaningfully stratified by lobe in a spontaneously breathing patient, and the 3-minute protocol rationale is based on FRC oxygen reservoir filling (denitrogenation), not preferential upper versus lower lobe distribution.
15. A pathologist reviews a liver biopsy from a patient who developed transaminase elevation following a prolonged hypotensive episode during general anesthesia with isoflurane. The biopsy shows necrosis concentrated in zone 3 — the centrilobular region surrounding the hepatic venule, which is the most distal part of the hepatic acinus and the furthest from the portal blood supply. Which of the following best explains why hepatic injury from anesthesia-related hepatic oxygen supply-demand imbalance preferentially produces zone 3 centrilobular necrosis rather than injury at other acinar zones?
A) Zone 3 hepatocytes are the primary site of CYP2E1 expression and therefore the first to be exposed to reactive metabolites of volatile agent metabolism, making them selectively vulnerable to metabolite-mediated injury regardless of blood flow changes
B) Zone 3 hepatocytes express the highest density of bile acid transporters; volatile agents inhibit these transporters, causing bile acid accumulation selectively in zone 3, which produces the observed centrilobular necrosis pattern
C) Zone 3 centrilobular necrosis in anesthesia-related hepatic injury reflects portal hypertension induced by volatile agents — as portal pressure rises, zone 3 venules are the first to become congested and thrombosed, producing the observed ischemic pattern
D) Zone 3 hepatocytes are at the end of the sinusoidal oxygen gradient — by the time blood reaches zone 3 from the portal triad in zone 1, much of its oxygen has already been extracted by upstream hepatocytes; when hepatic oxygen delivery falls (due to reduced hepatic blood flow from anesthesia-induced cardiac output reduction and splanchnic vasoconstriction), zone 3 cells, already operating at the lowest oxygen tension in the acinus, are the first to experience frank hypoxia and undergo ischemic necrosis
E) Zone 3 hepatocytes have the lowest mitochondrial density of any acinar zone and therefore the least capacity for anaerobic ATP generation when oxygen delivery falls; this metabolic vulnerability makes them selectively susceptible to volatile agent-induced mitochondrial uncoupling
ANSWER: D
Rationale:
Option D is correct. The hepatic acinus is organized around a gradient of oxygen tension that runs from zone 1 (periportal — the hepatocytes immediately adjacent to the portal tract where oxygenated portal and hepatic arterial blood enters) through zone 2 to zone 3 (centrilobular — the hepatocytes surrounding the central hepatic venule). As blood flows through the sinusoids from portal tract to central vein, oxygen is progressively extracted by upstream hepatocytes, so zone 3 hepatocytes operate at the lowest oxygen tension under normal conditions and have the narrowest margin between oxygen supply and demand. When hepatic oxygen delivery falls — as occurs with volatile anesthetic-induced reductions in cardiac output, splanchnic vasoconstriction, and direct hepatic blood flow reduction — zone 3 hepatocytes are the first to experience oxygen supply falling below the threshold for aerobic metabolism. This produces the zone 3 centrilobular pattern of ischemic necrosis that is characteristic of anesthesia-related hepatic oxygen supply-demand imbalance, as well as other causes of reduced hepatic perfusion (right heart failure, shock, Budd-Chiari syndrome). This mechanism underlies Type I halothane hepatotoxicity and is pharmacologically non-specific — it occurs with any anesthetic that reduces hepatic blood flow sufficiently in a vulnerable patient.
Option A: Option A is incorrect; while CYP2E1 is indeed preferentially expressed in zone 3 and this does contribute to the selective vulnerability of zone 3 to metabolite-mediated injury (relevant to immune-mediated hepatitis), the mechanism of ischemic centrilobular necrosis from oxygen supply-demand imbalance is the sinusoidal oxygen gradient, not metabolite distribution.
Option B: Option B is incorrect; bile acid transporter inhibition produces a cholestatic pattern of injury, not ischemic centrilobular necrosis.
Option C: Option C is incorrect; volatile agents do not produce portal hypertension, and the centrilobular necrosis pattern in anesthesia-related injury is ischemic, not congestive or thrombotic.
Option E: Option E is incorrect; zone 3 hepatocytes do not have the lowest mitochondrial density — they are actually metabolically active cells. Volatile agents do not uncouple mitochondrial respiration as a primary mechanism of the observed ischemic pattern.
16. A 26-year-old woman survived a confirmed MH crisis three months ago during elective knee surgery. She has recovered fully. She has three siblings aged 22, 24, and 30, all of whom will need elective surgery in the near future. Her parents are both living and have had uneventful general anesthetics in the past. She asks what recommendations should be made for her family regarding their anesthetic risk. Which of the following correctly describes the appropriate management strategy for first-degree relatives of a confirmed MH-susceptible individual?
A) Because the parents have both had uneventful general anesthetics, the mutation likely arose de novo in the patient; her siblings' risk is negligible and standard volatile anesthetic techniques are appropriate without further evaluation
B) Each first-degree relative — siblings and parents — has a 50% prior probability of carrying the MH susceptibility mutation; all should receive non-triggering anesthesia for any surgical procedure until formally evaluated; referral to a designated MH testing center for CHCT (in vitro caffeine-halothane contracture test on skeletal muscle biopsy) and/or genetic counseling is indicated; a negative anesthetic history in the parents does not exclude their carrier status given MH's variable penetrance
C) Only the siblings require evaluation; parents are not at risk because MH susceptibility in autosomal dominant disorders never skips generations — if neither parent had a crisis, neither can be a carrier
D) The siblings should undergo provocative halothane testing at a monitored anesthesia care unit; if they each tolerate a 30-minute halothane exposure without developing signs of MH, they are confirmed non-susceptible and can receive volatile agents in the future without restriction
E) Because MH is autosomal dominant, each sibling has a 75% probability of being MH-susceptible; all three should be referred for CHCT, and if any one sibling tests positive, the remaining two can be presumed positive without individual testing
ANSWER: B
Rationale:
Option B is correct. MH susceptibility is inherited as an autosomal dominant trait, meaning that each first-degree relative of a confirmed MH-susceptible individual has a 50% prior probability of carrying the causative mutation. This applies to siblings (who share 50% of genetic material with the affected individual) and to parents (one of whom is the obligate carrier of the mutation in an autosomal dominant condition). The appropriate recommendation for all first-degree relatives is: (1) use non-triggering anesthetic technique (TIVA with propofol, opioids, and nondepolarizing agents; nitrous oxide permitted) for any surgical procedure until formally evaluated, regardless of prior anesthetic history; (2) referral to a designated MH testing center (MHAUS-affiliated or equivalent internationally) for CHCT and/or genetic counseling. The critical point is that the parents' uneventful anesthetic history does not exclude carrier status — MH has variable penetrance, and a carrier parent may have received one or more volatile anesthetics without crisis. The obligate carrier parent simply has not yet been triggered.
Option A: Option A is incorrect; de novo mutation is possible but not assumed in the absence of confirming genetic evidence; furthermore, prior uneventful volatile anesthetic exposure in the parents does not exclude carrier status given variable penetrance.
Option C: Option C is incorrect; in autosomal dominant inheritance, the mutation is transmitted by a carrier parent — the parents are not automatically excluded from risk just because they did not have a crisis; variable penetrance is the explanation.
Option D: Option D is incorrect; in vivo provocative halothane testing is never the appropriate diagnostic approach — it risks triggering an MH crisis in the tested individual. CHCT is performed in vitro on excised muscle, not by exposing the patient to volatile anesthetics in vivo.
Option E: Option E is incorrect; each first-degree relative has an independent 50% probability, not 75%; and each individual requires their own CHCT for formal characterization — a positive test in one sibling does not confirm susceptibility in others.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.